Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BHVN | US
-0.36
-0.75%
Healthcare
Biotechnology
30/06/2024
04/10/2024
47.63
46.46
47.82
46.02
Biohaven Ltd. a clinical-stage biopharmaceutical company focuses on discovering developing and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000 a potassium channel activator for the treatment of focal epilepsy; BHV-7010 a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat an oral myeloperoxidase inhibitor which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa an anti-myostatin adnectin which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
High Short-term Volatility
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
88.1%1 month
64.8%3 months
58.1%6 months
63.3%-
-
12.56
0.08
0.05
-2.19
-
-
-774.44M
4.50B
4.50B
-
-
-
-
-193.67
14.61
11.96
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
12.17
Range1M
16.70
Range3M
19.49
Rel. volume
0.40
Price X volume
25.28M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Alkermes plc | ALKS | Biotechnology | 28.97 | 4.77B | -0.10% | 12.07 | 28.66% |
Corcept Therapeutics Incorporated | CORT | Biotechnology | 45.43 | 4.75B | -0.94% | 38.88 | 0.95% |
BridgeBio Pharma Inc | BBIO | Biotechnology | 25.23 | 4.74B | 0.60% | n/a | -158.23% |
ADMA Biologics Inc | ADMA | Biotechnology | 20.29 | 4.73B | 4.05% | 138.46 | 75.10% |
Madrigal Pharmaceuticals Inc | MDGL | Biotechnology | 208.41 | 4.53B | -0.35% | n/a | 13.77% |
Common Stock | IMVT | Biotechnology | 30.51 | 4.51B | 3.35% | n/a | 0.01% |
Crinetics Pharmaceuticals Inc | CRNX | Biotechnology | 53.14 | 4.25B | -1.63% | n/a | 6.42% |
Arcellx Inc. Common Stock | ACLX | Biotechnology | 78.23 | 4.21B | 2.62% | n/a | 15.25% |
Axsome Therapeutics Inc | AXSM | Biotechnology | 86.59 | 4.16B | -7.13% | n/a | 186.48% |
Denali Therapeutics Inc | DNLI | Biotechnology | 28.63 | 4.10B | -1.38% | n/a | 3.51% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Polaris Industries Inc | PII | Recreational Vehicles | 82.25 | 4.59B | 0.61% | 14.90 | 170.51% |
Harley-Davidson Inc | HOG | Recreational Vehicles | 34.78 | 4.58B | -4.61% | 7.97 | 218.58% |
BRP Inc | DOOO | Recreational Vehicles | 59.31 | 4.30B | 2.21% | 24.84 | 552.13% |
LCI Industries | LCII | Recreational Vehicles | 118.67 | 3.02B | -1.21% | 25.17 | 77.66% |
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -2.19 | 0.76 | Cheaper |
Ent. to Revenue | - | 3,674.48 | - |
PE Ratio | - | 38.01 | - |
Price to Book | 12.56 | 14.10 | Par |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 58.05 | 74.67 | Lower Risk |
Debt to Equity | 0.08 | -1.82 | Expensive |
Debt to Assets | 0.05 | 0.26 | Cheaper |
Market Cap | 4.50B | 3.73B | Market Leader |